Non-Alcoholic Steatohepatitis Treatment Market Size Projected To Reach $13.83 Billion By 2034 With A Cagr Of 40%

The Non-Alcoholic Steatohepatitis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Non-Alcoholic Steatohepatitis Treatment Market?
In recent times, the market size of the treatment for non-alcoholic steatohepatitis has experienced exponential growth. It is predicted that it will escalate from a mark of $2.6 billion in 2024, eventually reaching $3.6 billion in 2025, showing a compound annual growth rate (CAGR) of 38.5%. This significant increase during the historical period can be credited to a rise in NASH prevalence, enhanced diagnosis and awareness, changes in lifestyle, prevalence of obesity, advancements in clinical research, upgrades in healthcare infrastructure and accessibility, as well as increased regulatory support and procedural clinical trials.

The market size of treatment for non-alcoholic steatohepatitis is predicted to witness a hefty expansion in the forthcoming years, reaching a milestone of $13.83 billion by 2029, accelerating at a compound annual growth rate (CAGR) of 40.0%. The anticipated enlargement during this predictive period is linked to progressive drug innovation, heightened understanding of the disease, a surge in incidence and risk factors, and a transition towards individualized medicine. Predominant trends expected during this period encompass a patient-focused approach, advances in technology, targeted treatments, changes in regulations, and breakthroughs in scientific research.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595

What Are the Different Non-Alcoholic Steatohepatitis Treatment Market Segments?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented -

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

What Are the Primary Drivers Shaping the Non-Alcoholic Steatohepatitis Treatment Market?
The growth trajectory of the non-alcoholic steatohepatitis treatment market is being directly influenced by the escalating prevalence of insulin resistance worldwide. Insulin resistance, triggered by factors such as unhealthy habits, excessive intake of sugar, and genetic predisposition, leads to the inability of muscle, fat, and liver cells to respond effectively to insulin, hence resulting in abnormally high blood sugar levels. This condition, often linked with diabetes and other liver issues, is managed using non-alcoholic steatohepatitis treatment, a main reason for its demand spike. For instance, as per a January 2022 report of the International Diabetes Federation, a Belgium-based global diabetes organization, diabetes is presently affecting one in every ten individuals (20-79 years old), a figure expected to surge up to 643 million by 2030 and reach 783 million by 2045. Adding further, predictions by the American Cancer Society, a prominent US-based cancer advocacy non-profit, show that new cases of liver cancer would increase to 41,630 by 2024 from 41,210 in 2023. Therefore, with the number of patients suffering from insulin resistance continually rising due to multiple liver and diabetes ailments, the non-alcoholic steatohepatitis treatment market will be pushed towards significant expansion.

Which Companies Are Leading in the Non-Alcoholic Steatohepatitis Treatment Market?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

What Are the Major Trends Shaping the Non-Alcoholic Steatohepatitis Treatment Market?
The rise in the creation of non-alcoholic steatohepatitis (NASH) drugs is a growing trend in the non-alcoholic steatohepatitis treatment market. Various enterprises are putting resources into the creation of novel drugs for treating liver diseases, while also minimizing the side effects of these drugs. For example, in May 2022, Pfizer Inc., a renowned U.S. pharmaceutical and biotechnology corporation, was awarded a grant by the U.S. Food and Drug Administration (FDA) for the expedited development of their NASH drugs, ervogastat and clesacostat. The Fast track process fostered the development of Pfizer's experimental combination therapy for NASH with liver fibrosis, known as ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Are the Top Revenue-Generating Geographies in the Non-Alcoholic Steatohepatitis Treatment Market?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Non-Alcoholic Steatohepatitis Treatment Market?
2. What is the CAGR expected in the Non-Alcoholic Steatohepatitis Treatment Market?
3. What Are the Key Innovations Transforming the Non-Alcoholic Steatohepatitis Treatment Industry?
4. Which Region Is Leading the Non-Alcoholic Steatohepatitis Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.